

Status and Prospects of Liver Cirrhosis Treatment by U and Mesenchymal Cells

Tissue Engineering - Part B: Reviews

20, 206-210

DOI: [10.1089/ten.teb.2013.0527](https://doi.org/10.1089/ten.teb.2013.0527)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pathogenesis of liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 7312.	1.4	409
2	Cell therapy to remove excess copper in Wilson's disease. Annals of the New York Academy of Sciences, 2014, 1315, 70-80.	1.8	32
3	Enhanced survival of mice infused with bone marrow-derived as compared with adipose-derived mesenchymal stem cells. Hepatology Research, 2015, 45, 1353-1359.	1.8	24
4	Characterization and Comparison of Canine Multipotent Stromal Cells Derived from Liver and Bone Marrow. Stem Cells and Development, 2016, 25, 139-150.	1.1	18
5	Mesenchymal Stem Cells with Enhanced Bcl-2 Expression Promote Liver Recovery in a Rat Model of Hepatic Cirrhosis. Cellular Physiology and Biochemistry, 2016, 40, 1117-1128.	1.1	27
6	The current state of liver regeneration therapy. Acta Hepatologica Japonica, 2016, 57, 269-279.	0.0	0
7	Cell transplantation as a non-invasive strategy for treating liver fibrosis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 639-648.	1.4	9
8	MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis. Journal of Cellular and Molecular Medicine, 2017, 21, 2963-2973.	1.6	155
9	Cell Therapy for Liver Disease Using Bioimaging Rats. Cell Medicine, 2017, 9, 3-7.	5.0	4
10	Effects of human umbilical cord blood mononuclear cells on respiratory system mechanics in a murine model of neonatal lung injury. Experimental Lung Research, 2017, 43, 66-81.	0.5	13
11	Copper-induced liver fibrosis affects the behavior of bone marrow cells in primary culture. Frontiers in Biology, 2017, 12, 271-279.	0.7	8
12	Molecular and functional characterization of CD133 + stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. Cytotherapy, 2017, 19, 1447-1461.	0.3	7
13	Human Muse Cells, Nontumorigenic Pluripotent-Like Stem Cells, Have Liver Regeneration Capacity through Specific Homing and Cell Replacement in a Mouse Model of Liver Fibrosis. Cell Transplantation, 2017, 26, 821-840.	1.2	69
14	Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases. Tissue Engineering and Regenerative Medicine, 2017, 14, 653-665.	1.6	10
15	Status of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return" in advanced liver cirrhosis. Journal of Gastroenterology, 2017, 52, 129-140.	2.3	58
16	BMSCs protect against liver injury via suppressing hepatocyte apoptosis and activating TGF- β 1/Bax signaling pathway. Biomedicine and Pharmacotherapy, 2017, 96, 1395-1402.	2.5	18
17	Tissue Bioengineering in Transplantation. , 2017, , 181-213.		0
18	Tissue Engineering and Regenerative Medicine Solutions for the Abdominal Organs. , 2017, , 325-347.		1

#	ARTICLE	IF	CITATIONS
19	Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-19.	0.8	51
20	New Perspectives in Liver Transplantation: From Regeneration to Bioengineering. <i>Bioengineering</i> , 2019, 6, 81.	1.6	19
21	Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats. <i>Annals of Hepatology</i> , 2019, 18, 620-626.	0.6	12
22	Liver Macrophages: Old Dogmas and New Insights. <i>Hepatology Communications</i> , 2019, 3, 730-743.	2.0	256
23	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 70-80.	4.5	67
24	Clinical and morphological case of developing liver cirrhosis associated with viral hepatitis in a young patient. <i>Russian Journal of Infection and Immunity</i> , 2021, 11, 784-788.	0.2	0
25	Effect of Autologous Bone Marrow Stem Cell Therapy in Patients with Liver Cirrhosis: A Meta-analysis. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-11.	0.7	17
26	Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2014, 20, 14051.	1.4	42
27	Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives. <i>World Journal of Gastroenterology</i> , 2015, 21, 10253.	1.4	47
29	Impact of total splenectomy on peripheral lymphocytes and their subsets in patients with hypersplenism associated with cirrhotic portal hypertension. <i>Scientific Reports</i> , 2021, 11, 21246.	1.6	6
30	The effectiveness of autologous mesenchymal stem cells in the treatment of liver cirrhosis and the method of their visualization in the patient's body. <i>Vestnik of Russian Military Medical Academy</i> , 2020, 22, 35-40.	0.1	0
31	ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF- β ² /Smad signaling pathway. <i>Cell Death Discovery</i> , 2022, 8, 51.	2.0	15
32	Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 268-287.	2.8	19